New mRNA vaccine aims to stop lyme disease in its tracks

NCT ID NCT07561294

NEW Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen May 06, 2026 · Last updated May 06, 2026

Summary

This study tests an experimental mRNA vaccine designed to prevent Lyme disease, a tick-borne illness. About 350 healthy adults aged 18 to 70 will receive either the vaccine or a placebo. Researchers will monitor safety and measure the body's immune response to see if the vaccine can protect against infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYME DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bluewater Clinical Research Group Inc.

    Sarnia, Ontario, N7T 4X3, Canada

  • Colchester Research Group

    Truro, Nova Scotia, B2N 1L2, Canada

  • Diex Recherche Inc. - Division Joliette

    Joliette, Quebec, J6E 6A9, Canada

  • Diex Recherche Inc. - Division Quebec

    Québec, G1V 4T3, Canada

  • Diex Recherche Inc. - Division Sherbrooke

    Sherbrooke, Quebec, J1L 0H8, Canada

  • Diex Recherche Inc. - Division Victoriaville

    Victoriaville, Quebec, G6P 3Z8, Canada

  • Dr. Anil K. Gupta Medicine Professional Corporation Inc.

    Toronto, Ontario, M9V 4B4, Canada

  • Stouffville Medical Research Institute Inc.

    Stouffville, Ontario, L4A 1H2, Canada

Conditions

Explore the condition pages connected to this study.